Pembrolizumab (anti‐programed cell‐death protein‐1 ligand‐1 (PD‐L1)) is indicated for patients with ≥ 1% tumor cells expressing PD‐L1; nivolumab and atezolizumab (directed against PD‐1) are indicated for all comers.3, 4. The gene discussed is CD274; the disease is neoplasm.